SION · Sionna Therapeutics, Inc. · Financials
$7.85
+0.23 (+3.02%)
At close · Sep 11
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$354.92M
Shares
45.21M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$75.27M
-22%
FY2025
Diluted EPS
-$1.88
+88.2%
FY2025
Operating Cash Flow
-$66.3M
-25.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $72.04M | $60.26M | $57.29M | |
| $37.45M | $28.72M | $13.27M | |
| $109.49M | $88.98M | $70.56M | |
| -$109.49M | -$88.98M | -$70.56M | |
| $12.04M | $13.3M | $8.17M | |
| $12.1M | $13.71M | $8.87M | |
| — | $0 | $0 | |
| -$97.38M | -$75.27M | -$61.69M | |
| -$98.01M | -$75.1M | -$61.32M | |
| USD/shares | -$2.11 | -$1.88 | -$15.99 |
| USD/shares | -$2.11 | -$1.88 | -$15.99 |
| shares | — | 39.96M | 3.86M |
| shares | — | 39.96M | 3.86M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.98×
EV/EBIT
—
Peer median 9.22×
P/E (TTM)
—
Peer median 11.89×
Peer medians compare against the 320 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
2036042
CUSIP
829401108
13F (30d)
68 filings
68 filers
Visit website
Investor relations